About Bausch Health Companies Inc.
https://www.bauschhealth.comBausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
CEO
Thomas J. Appio
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-10-16 | Forward | 2:1 |
| 2000-10-05 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 7
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
PAULSON & CO. INC.
Shares:70.76M
Value:$527.13M
GOLDENTREE ASSET MANAGEMENT LP
Shares:34.83M
Value:$259.51M
NOMURA HOLDINGS INC
Shares:15.71M
Value:$117.03M
Summary
Showing Top 3 of 283
About Bausch Health Companies Inc.
https://www.bauschhealth.comBausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $912M ▼ | $961M ▼ | $179M ▲ | 19.63% ▲ | $-0.24 ▼ | $2.52B ▲ |
| Q2-2025 | $2.53B ▲ | $1.32B ▲ | $148M ▲ | 5.85% ▲ | $0.4 ▲ | $764M ▲ |
| Q1-2025 | $2.26B ▼ | $1.28B ▲ | $-58M ▼ | -2.57% ▼ | $-0.16 ▼ | $602M ▼ |
| Q4-2024 | $2.56B ▲ | $1.27B ▼ | $93M ▲ | 3.63% ▲ | $0.25 ▲ | $901M ▲ |
| Q3-2024 | $2.51B | $1.5B | $-85M | -3.39% | $-0.23 | $866M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.34B ▼ | $26.8B ▼ | $26.44B ▼ | $-564.45M ▲ |
| Q2-2025 | $1.73B ▲ | $27.27B ▲ | $27.12B ▲ | $-764M ▲ |
| Q1-2025 | $1.13B ▼ | $26.42B ▼ | $26.66B ▼ | $-1.18B ▲ |
| Q4-2024 | $1.18B ▲ | $26.52B ▼ | $26.84B ▲ | $-1.28B ▼ |
| Q3-2024 | $719M | $26.54B | $26.78B | $-1.17B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $181M ▲ | $405M ▲ | $-83M ▲ | $-719M ▼ | $-403M ▼ | $314M ▲ |
| Q2-2025 | $128M ▲ | $289M ▲ | $-100M ▲ | $358M ▲ | $586M ▲ | $190M ▲ |
| Q1-2025 | $-86M ▼ | $211M ▼ | $-130M ▲ | $-146M ▼ | $-44M ▼ | $87M ▼ |
| Q4-2024 | $98M ▲ | $601M ▲ | $-200M ▼ | $85M ▲ | $451M ▲ | $494M ▲ |
| Q3-2024 | $-85.68M | $403.69M | $-102.43M | $-186.81M | $125.91M | $332.39M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Product | $0 ▲ | $2.66Bn ▲ | $2.23Bn ▼ | $2.50Bn ▲ |
 Product and Service Other | $0 ▲ | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 Branded and Other Generic Products | $230.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Device Products | $610.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Other Revenues | $30.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Over the Counter Products | $500.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Pharmaceutical Products | $1.18Bn ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2024 | Q1-2024 | Q2-2024 |
|---|---|---|---|---|
 CANADA | $110.00M ▲ | $100.00M ▼ | $90.00M ▼ | $100.00M ▲ |
 CHINA | $140.00M ▲ | $130.00M ▼ | $100.00M ▼ | $120.00M ▲ |
 FRANCE | $50.00M ▲ | $50.00M ▲ | $60.00M ▲ | $70.00M ▲ |
 GERMANY | $30.00M ▲ | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 ITALY | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 JAPAN | $50.00M ▲ | $50.00M ▲ | $40.00M ▼ | $50.00M ▲ |
 KOREA REPUBLIC OF | $40.00M ▲ | $40.00M ▲ | $30.00M ▼ | $30.00M ▲ |
 MEXICO | $70.00M ▲ | $90.00M ▲ | $80.00M ▼ | $80.00M ▲ |
 Other Countries | $290.00M ▲ | $260.00M ▼ | $260.00M ▲ | $270.00M ▲ |
 POLAND | $90.00M ▲ | $90.00M ▲ | $90.00M ▲ | $80.00M ▼ |
 SPAIN | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $30.00M ▲ |
 United States and Puerto Rico | $1.54Bn ▲ | $1.53Bn ▼ | $1.25Bn ▼ | $1.44Bn ▲ |
CEO
Thomas J. Appio
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-10-16 | Forward | 2:1 |
| 2000-10-05 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 7
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
PAULSON & CO. INC.
Shares:70.76M
Value:$527.13M
GOLDENTREE ASSET MANAGEMENT LP
Shares:34.83M
Value:$259.51M
NOMURA HOLDINGS INC
Shares:15.71M
Value:$117.03M
Summary
Showing Top 3 of 283